[1]胡伟婷,李兴.血管生成素样蛋白6与肥胖及其相关疾病的研究进展[J].国际内分泌代谢杂志,2021,41(03):229-232.[doi:10.3760/cma.j.cn121383-20200524-05072]
 Hu Weiting,Li Xing..Research progress of angiopoietin-like protein 6 in obesity and related diseases[J].International Journal of Endocrinology and Metabolism,2021,41(03):229-232.[doi:10.3760/cma.j.cn121383-20200524-05072]
点击复制

血管生成素样蛋白6与肥胖及其相关疾病的研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年03期
页码:
229-232
栏目:
综述
出版日期:
2021-05-20

文章信息/Info

Title:
Research progress of angiopoietin-like protein 6 in obesity and related diseases
作者:
胡伟婷1李兴2
1山西医科大学,太原 030001; 2山西医科大学第二医院内分泌科,太原 030001
Author(s):
Hu Weiting1 Li Xing2.
1Shanxi Medical University, Taiyuan 030001, China; 2Department of Endocrinology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
血管生成素样蛋白6 胰岛素抵抗 肥胖 2型糖尿病
Keywords:
Angiogenin-like protein 6 Insulin resistance Obesity Type 2 diabetes mellitus
DOI:
10.3760/cma.j.cn121383-20200524-05072
摘要:
血管生成素样蛋白6(angiogenin-like protein 6,ANGPTL6)是血管生成素样蛋白家族中的一员,其表达与肥胖、糖尿病及多囊卵巢综合征等疾病密切相关。尽管对啮齿类动物研究表明ANGPTL6可以改善肥胖和胰岛素抵抗,但其在肥胖及其相关疾病中的表达却升高。研究ANGPTL6在肥胖及其相关疾病中的作用和机制,有望为肥胖、糖尿病等疾病的治疗提供新的治疗靶点和思路。
Abstract:
Angiopoietin-like protein 6(ANGPTL6)is a member of the angiopoietin-like protein family, and its expression is closely related to diseases such as obesity, diabetes, and polycystic ovary syndrome. Although rodent studies have shown that ANGPTL6 can improve obesity and insulin resistance, its expression in obesity and related diseases is increased. Studying the role and mechanism of ANGPTL6 in obesity and related diseases is expected to provide new therapeutic targets and ideas for the treatment of obesity, diabetes and other diseases.

参考文献/References:

[1] Deng X,Wang P,Yuan H.Epidemiology,risk factors across the spectrum of age-related metabolic diseases[J].J Trace Elem Med Biol,2020,61:126497.DOI:10.1016/jtemb.2020.126497.
[2] Endo M. The roles of ANGPTL families in cancer progression[J].J UOEH,2019,41(3):317-325.DOI:10.7888/juoeh.41.317.
[3] Oike Y,Akao M,Yasunaga K,et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance[J].Nat Med,2005,11(4):400-408.DOI:10.1038/nm1214.
[4] Qaddoumi MG,Alanbaei M,Hammad MM,et al. Investigating the role of myeloperoxidase and angiopoietin-like protein 6 in obesity and diabetes[J].Sci Rep,2020,10(1):6170.DOI:10.1038/s41598-020-63149-7.
[5] Sharma V,Pangtey GS,Gupta R,et al. Correlation of long-term glycemic control as measured by glycated hemoglobin with serum angiopoietin-like 6 protein levels in type 2 diabetes mellitus patients[J].Indian J Pharmacol,2017,49(3):250-253.DOI:10.4103/ijp.IJP_261_16.
[6] Kim JH. Letter:increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study(Diabetes Metab J 2019; 43:521-9)[J].Diabetes Metab J,2019,43(5):727-728.DOI:10.4093/dmj.2019.0172.
[7] Santulli G. Angiopoietin-like proteins:a comprehensive look[J].Front Endocrinol(Lausanne),2014,5:4.DOI:10.3389/fendo.2014.00004.
[8] Legry V,Goumidi L,Huyvaert M,et al. Association between angiopoietin-like 6(ANGPTL6)gene polymorphisms and metabolic syndrome-related phenotypes in the French MONICA Study[J].Diabetes Metab,2009,35(4):287-292.DOI:10.1016/j.diabet.2008.12.005.
[9] Oike Y,Yasunaga K,Ito Y,et al. Angiopoietin-related growth factor(AGF)promotes epidermal proliferation,remodeling,and regeneration[J].Proc Natl Acad Sci U S A,2003,100(16):9494-9499.DOI:10.1073/pnas.1531901100.
[10] Hato T,Tabata M,Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism[J].Trends Cardiovasc Med,2008,18(1):6-14.DOI:10.1016/j.tcm.2007.10.003.
[11] Kadomatsu T,Tabata M,Oike Y. Angiopoietin-like proteins:emerging targets for treatment of obesity and related metabolic diseases[J].FEBS J,2011,278(4):559-564.DOI:10.1111/j.1742-4658.2010.07979.x.
[12] Kang SG,Yi HS,Choi MJ,et al. ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21[J].J Endocrinol,2017,233(1):105-118.DOI:10.1530/JOE-16-0549.
[13] Cinkajzlova A,Lacinova Z,Klouckova J,et al. Angiopoietin-like protein 6 in patients with obesity,type 2 diabetes mellitus,and anorexia nervosa:the influence of very low-calorie diet,bariatric surgery,and partial realimentation[J].Endocr Res,2017,42(1):22-30.DOI:10.3109/07435800.2016.1169544.
[14] Namkung J,Koh SB,Kong ID,et al. Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome[J].Metabolism,2011,60(4):564-568.DOI:10.1016/j.metabol.2010.05.013.
[15] Gonzalez-Cantero J,Martin-Rodriguez JL,Gonzalez-Cantero A,et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults:study of its relationship with liver triglyceride content,waist circumference and BMI[J].PLoS One,2018,13(2):e0192663.DOI:10.1371/journal.pone.0192663.
[16] Al-Sulaiti H,Diboun I,Banu S,et al. Triglyceride profiling in adipose tissues from obese insulin sensitive,insulin resistant and type 2 diabetes mellitus individuals[J].J Transl Med,2018,16(1):175.DOI:10.1186/s12967-018-1548-x.
[17] Fan KC,Wu HT,Wei JN,et al. Serum angiopoietin-like protein 6,risk of type 2 diabetes,and response to hyperglycemia:a prospective cohort study[J].J Clin Endocrinol Metab,2020,105(5):dgaa103.DOI:10.1210/clinem/dgaa103.
[18] Ebert T,Kralisch S,Loessner U,et al. Relationship between serum levels of angiopoietin-related growth factor and metabolic risk factors[J].Horm Metab Res,2014,46(10):685-690.DOI:10.1055/s-0034-1382078.
[19] Abdullah B,Deveci K,Atilgan R,et al. Serum angiopoietin-related growth factor(AGF)levels are elevated in gestational diabetes mellitus and associated with insulin resistance[J].Ginekol Pol,2012,83(10):749-753.
[20] Boztosun A,Deveci K,Klçl F,et al. Serum levels of angiopoietin-related growth factor(AGF)are increased in polycystic ovary syndrome[J].J Investig Med,2012,60(5):813-817.DOI:10.2310/JIM.0b013e31824e9900.
[21] Elci E,Kaya C,Cim N,et al. Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries[J].Gynecol Endocrinol,2017,33(1):43-47.DOI:10.1080/09513590.2016.1203893.

相似文献/References:

[1]刘丹丹,王丽,史兴晔,等.脂肪酸受体GPR120影响胰岛素受体底物-1的表达[J].国际内分泌代谢杂志,2014,(06):371.[doi:10.3760/cma.j.issn.1673-4157.2014.06.003]
 Liu Dandan*,Wang Li,Shi Xingye,et al.Regulation of fatty acid receptor GPR120 on the expression of insulin receptor substrate-1[J].International Journal of Endocrinology and Metabolism,2014,(03):371.[doi:10.3760/cma.j.issn.1673-4157.2014.06.003]
[2]李新萍,张萍,李晓玉.螺内酯对特发性醛固酮增多症患者胰岛β细胞功能的影响[J].国际内分泌代谢杂志,2014,(06):379.[doi:10.3760/cma.j.issn.1673-4157.2014.06.005]
 Li Xinping,Zhang Ping,Li Xiaoyu..Effects of spironolactone on islet β cell function in patients with idiopathic hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2014,(03):379.[doi:10.3760/cma.j.issn.1673-4157.2014.06.005]
[3]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
 Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(03):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[4]张琳,王晓琳,李小英.雄激素与糖脂代谢的关系[J].国际内分泌代谢杂志,2014,(05):351.[doi:10.3760/cma.j.issn.1673-4157.2014.05.018]
 Zhang Lin,Wang Xiaolin,Li Xiaoying..The relationship between testosterone and glycolipid,metabolism[J].International Journal of Endocrinology and Metabolism,2014,(03):351.[doi:10.3760/cma.j.issn.1673-4157.2014.05.018]
[5]梁绮君 余寿益 李淑华 胡晨鸣 杨焱.甲状腺结节与代谢综合征的相关性研究[J].国际内分泌代谢杂志,2015,(05):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
 Liang Qijun,Yu Shouyi,Li Shuhua,et al.Association of thyroid nodule and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2015,(03):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
[6]王锐 陆强 王术艺 朱东林 蒋韬 马宁 刘悦 李燕莉 贾晓娇 姚立新.血清25羟维生素D及vaspin水平与妊娠糖尿病关系的研究[J].国际内分泌代谢杂志,2015,(05):306.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.005]
 Wang Rui,Lu Qiang,Wang Shuyi,et al.Relationship between serum 25-hydroxyvitamin D, vaspin and gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):306.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.005]
[7]黄祺 程海燕 卜瑞芳.1-磷酸鞘胺醇与胰岛素抵抗[J].国际内分泌代谢杂志,2015,(05):348.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.015]
 Huang Qi,Cheng Haiyan,Bu Ruifang..Sphingosine-1-phosphate and insulin resistance[J].International Journal of Endocrinology and Metabolism,2015,(03):348.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.015]
[8]李少卿 王坚.2型糖尿病患者血25-羟维生素D3缺乏 对胰岛素抵抗及骨量的影响[J].国际内分泌代谢杂志,2015,(06):384.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.006]
 Li Shaoqing*,Wang Jian..The influence of 25-hydroxyl vitamin D3 deficiency on insulin resistance and bone mass in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):384.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.006]
[9]李晶,董荣娜,于德民.有氧运动对胰岛素抵抗小鼠visfatin 表达的影响[J].国际内分泌代谢杂志,2016,36(01):10.[doi:10.3760/cma.j.issn.1673-4157.2016.01.003]
 Li Jing,Dong Rongna,Yu Demin..Effects of aerobic exercise on the expression of visfatin in mice with insulin resistance[J].International Journal of Endocrinology and Metabolism,2016,36(03):10.[doi:10.3760/cma.j.issn.1673-4157.2016.01.003]
[10]张琳,费雯婕,宋光耀.网膜素与代谢综合征[J].国际内分泌代谢杂志,2016,36(01):42.[doi:10.3760/cma.j.issn.1673-4157.2016.01.010]
 Zhang Lin*,Fei Wenjie,Song Guangyao..Omentin and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2016,36(03):42.[doi:10.3760/cma.j.issn.1673-4157.2016.01.010]

备注/Memo

备注/Memo:
通信作者:李兴,Email:13503504180@163.com 基金项目:山西省应用基础研究项目(201801D121214)
更新日期/Last Update: 2021-05-20